Related Experiment Video
Updated: Jan 3, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.1K
Relationship between metformin and abdominal aortic aneurysm.
Juliette Raffort1, Réda Hassen-Khodja2, Elixène Jean-Baptiste2
1Department of Clinical Biochemistry, University Hospital of Nice, Nice, France; Université Côte d'Azur, CHU, Inserm, C3M, Nice, France.
Journal of Vascular Surgery
|November 16, 2019
Summary
Metformin, an antidiabetic drug, shows a potential therapeutic role in managing abdominal aortic aneurysm (AAA). Research explores its effects on metabolism and inflammation for AAA treatment strategies.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Endocrinology
Background:
- Abdominal aortic aneurysm (AAA) is a critical condition with limited pharmacologic treatments.
- Epidemiological data suggest a protective association between metformin use and AAA incidence.
- Metformin's known effects extend beyond glucose control to metabolism and inflammation, relevant to cardiovascular health.
Purpose of the Study:
- To review the current understanding of the relationship between metformin and abdominal aortic aneurysm.
- To discuss the potential of metformin as a therapeutic agent for AAA based on its known mechanisms.
Main Methods:
- Literature review of existing studies on metformin and AAA.
- Analysis of metformin's effects on the aortic wall.
- Discussion of translational applications and clinical trial data.
Main Results:
- Metformin's influence on metabolic and inflammatory pathways may impact AAA development.
- Evidence suggests a potential benefit of metformin in reducing AAA risk or progression.
- Translational research and ongoing clinical trials are crucial for validation.
Conclusions:
- Metformin presents a promising therapeutic avenue for abdominal aortic aneurysm management.
- Further clinical investigation is warranted to confirm metformin's efficacy and safety in AAA patients.
- Understanding metformin's role could lead to novel treatment strategies for this life-threatening condition.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
543
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
543
01:26Aneurysm III: Interprofessional Care
227
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
227
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
206
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
206
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
163
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
163
01:30Aneurysm I: Introduction
240
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
240
01:25Aortic Regurgitation III: Medical Management
336
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
336